{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:42:47Z","timestamp":1790037767889,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,2,24]],"date-time":"2007-02-24T00:00:00Z","timestamp":1172275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2007,3,14]]},"DOI":"10.1007\/s00259-007-0372-y","type":"journal-article","created":{"date-parts":[[2007,2,23]],"date-time":"2007-02-23T09:43:10Z","timestamp":1172223790000},"page":"616-622","source":"Crossref","is-referenced-by-count":77,"title":["EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)"],"prefix":"10.1007","volume":"34","author":[{"given":"Jan","family":"Tennvall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Bischof Delaloye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giammarile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Oyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn","family":"Brans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,24]]},"reference":[{"key":"372_CR1","first-page":"1017","volume":"15","author":"PC Chinn","year":"1999","unstructured":"Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. Preclinical evaluation of 90Y-labeled anti DC20 monoclonal antibody for treatment of non-Hodgkin\u2019s lymphoma. Int J Oncol 1999;15:1017\u201325.","journal-title":"Int J Oncol"},{"key":"372_CR2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00262-002-0348-5","volume":"52","author":"DM Goldenberg","year":"2003","unstructured":"Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003;52:281\u20139.","journal-title":"Cancer Immunol Immunother"},{"key":"372_CR3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-0038-1625198","volume":"43","author":"M Fischer","year":"2004","unstructured":"Fischer M, Behr T, Gr\u00fcnwald, Knapp WH, Trumper L, von Schilling C; German Society for Hematology and Oncology. Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin\u2019s lymphoma [in German]. Nuklearmedizin 2004;43:171\u20136.","journal-title":"Nuklearmedizin"},{"key":"372_CR4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s001080170129","volume":"42","author":"F Griesinger","year":"2001","unstructured":"Griesinger F, Tr\u00fcmper L, Becker W. Radioimmunkonjugate: Therapie von Non-Hodgkin-Lymphomen und kolorektalen Karzinomen. Der Internist 2001;42:860\u201373.","journal-title":"Der Internist"},{"key":"372_CR5","first-page":"1507","volume":"43","author":"ME Juweid","year":"2002","unstructured":"Juweid ME. Radioimmunotherapy of B-cell Non-Hodgkin\u2019s lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43:1507\u201329.","journal-title":"J Nucl Med"},{"key":"372_CR6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/annonc\/mdi148","volume":"16","author":"A Hagenbeek","year":"2005","unstructured":"Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of 90Yttrium-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005;16:786\u201392.","journal-title":"Ann Oncol"},{"key":"372_CR7","doi-asserted-by":"crossref","unstructured":"Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Immunotherapy of Non-Hodgkin\u2019s lymphoma. Hematology 2001;221\u201340.","DOI":"10.1182\/asheducation-2001.1.221"},{"key":"372_CR8","first-page":"267","volume":"43","author":"HN Wagner","year":"2002","unstructured":"Wagner HN, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin\u2019s lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002;43:267\u201372.","journal-title":"J Nucl Med"},{"key":"372_CR9","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336\u201342.","journal-title":"Blood"},{"key":"372_CR10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cncr.10305","volume":"94","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;94:1349\u201357.","journal-title":"Cancer"},{"issue":"3","key":"372_CR11","first-page":"465","volume":"44","author":"GA Wiseman","year":"2003","unstructured":"Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin\u2019s lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44(3):465\u20137.","journal-title":"J Nucl Med"},{"issue":"1\u20132","key":"372_CR12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1040-8428(01)00107-X","volume":"39","author":"GA Wiseman","year":"2001","unstructured":"Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. Crit Rev Oncol Hematol 2001;39(1\u20132):181\u201394.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 1","key":"372_CR13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002800100312","volume":"48","author":"TE Witzig","year":"2001","unstructured":"Witzig TE. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2001;48(Suppl 1):91\u20135.","journal-title":"Cancer Chemother Pharmacol"},{"key":"372_CR14","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002;20:2453\u201363.","journal-title":"J Clin Oncol"},{"key":"372_CR15","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002;20:3262\u20139.","journal-title":"J Clin Oncol"},{"key":"372_CR16","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","volume":"17","author":"TE Witzig","year":"1999","unstructured":"Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. PhaseI\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 1999;17:3793\u2013803.","journal-title":"J Clin Oncol"},{"key":"372_CR17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"TE Witzig","year":"2003","unstructured":"Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 2003;21:1263\u201370.","journal-title":"J Clin Oncol"},{"key":"372_CR18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244\u201353.","journal-title":"J Clin Oncol"},{"key":"372_CR19","unstructured":"European Medicines Agency. http:\/\/www.emea.eu.int\/humandocs\/PDFs\/EPA.R\/zevalin"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0372-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-007-0372-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0372-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T06:01:43Z","timestamp":1587362503000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-007-0372-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,24]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,3,14]]}},"alternative-id":["372"],"URL":"https:\/\/doi.org\/10.1007\/s00259-007-0372-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,24]]}}}